Michael P. Veve

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa

Jason M. Pogue, Keith S. Kaye, Michael P. Veve et al. · Clinical Infectious Diseases · 2019 · 205 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Epidemiology and outcomes of non-HACEK infective endocarditis in the southeast United States

Michael P. Veve, Eric D. McCurry, Grace E. Cooksey et al. · PLoS ONE · 2020 · 58 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +17

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>

Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette et al. · Open Forum Infectious Diseases · 2021 · 57 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

Sara Alosaimy, Taylor Morrisette, Abdalhamid M Lagnf et al. · Microbiology Spectrum · 2022 · 54 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Predictors of Clinically Significant Drug-Drug Interactions Among Patients Treated with Nonnucleoside Reverse Transcriptase Inhibitor–, Protease Inhibitor–, and Raltegravir-Based Antiretroviral Regimens

Nimish Patel, Sandra Abdelsayed, Michael P. Veve et al. · Annals of Pharmacotherapy · 2011 · 53 citations

Pharmacy, Pharmacology, Pharmacotherapy +17